Addressing a yellow fever vaccine shortage — United States, 2016–2017

Mark D. Gershman, Kristina M. Angelo, Julian Ritchey, David P. Greenberg, Riyadh D. Muhammad, Gary Brunette, Martin S. Cetron, Mark J. Sotir

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

What is already known about this topic? Effective and safe yellow fever vaccines are available to prevent yellow fever disease among persons traveling to countries with yellow fever virus transmission and to comply with individual country yellow fever vaccination entry requirements; only one yellow fever vaccine (YF-VAX) is currently licensed for use in the United States. Periodic, temporary yellow fever vaccine shortages have occurred in the United States as a result of manufacturing problems, including a manufacturing complica­tion in 2016 that resulted in the loss of a large number of U.S.-licensed yellow fever vaccine doses. What is added by this report? To avoid a lapse in yellow fever vaccine availability to persons in the U.S. population for whom yellow fever vaccination is indicated, public health officials and private partners collaborated in pursuing an expanded access investigational new drug (eIND) application for the importation of Stamaril yellow fever vaccine into the United States. Stamaril is produced by Sanofi Pasteur, the manufacturer of the U.S.-licensed YF-VAX, and it uses the same vaccine substrain. A systematic, tiered process was developed to select clinics to participate in the eIND protocol, with the goal of reasonable accessibility to yellow fever vaccination for all U.S. residents, while assuring that clinic personnel could be ade­quately trained to participate in the protocol. What are the implications for public health practice? Providers need to be aware that there is a yellow fever vaccine shortage and there is a plan for providing safe vaccine at a limited number of clinics until the supply is replenished. Domestic production of yellow fever vaccine in the United States should resume in 2018, and as the eIND protocol is implemented, CDC and Sanofi Pasteur will need to continue to collaborate throughout site recruitment and training, partner to resolve issues that arise, and maintain communication with health care providers and the general public.

Original languageEnglish (US)
Pages (from-to)457-459
Number of pages3
JournalMorbidity and Mortality Weekly Report
Volume66
Issue number17
DOIs
StatePublished - May 5 2017

Fingerprint

Yellow Fever Vaccine
vaccination
shortage
drug
Yellow Fever
manufacturing
public health
human being
Investigational Drugs
Vaccination
personnel
health care
resident
supply
Disease
Investigational New Drug Application
Vaccines
communication
Yellow fever virus
Public Health Practice

ASJC Scopus subject areas

  • Epidemiology
  • Health(social science)
  • Health, Toxicology and Mutagenesis
  • Health Information Management

Cite this

Gershman, M. D., Angelo, K. M., Ritchey, J., Greenberg, D. P., Muhammad, R. D., Brunette, G., ... Sotir, M. J. (2017). Addressing a yellow fever vaccine shortage — United States, 2016–2017. Morbidity and Mortality Weekly Report, 66(17), 457-459. https://doi.org/10.15585/mmwr.mm6617e2

Addressing a yellow fever vaccine shortage — United States, 2016–2017. / Gershman, Mark D.; Angelo, Kristina M.; Ritchey, Julian; Greenberg, David P.; Muhammad, Riyadh D.; Brunette, Gary; Cetron, Martin S.; Sotir, Mark J.

In: Morbidity and Mortality Weekly Report, Vol. 66, No. 17, 05.05.2017, p. 457-459.

Research output: Contribution to journalArticle

Gershman, MD, Angelo, KM, Ritchey, J, Greenberg, DP, Muhammad, RD, Brunette, G, Cetron, MS & Sotir, MJ 2017, 'Addressing a yellow fever vaccine shortage — United States, 2016–2017', Morbidity and Mortality Weekly Report, vol. 66, no. 17, pp. 457-459. https://doi.org/10.15585/mmwr.mm6617e2
Gershman MD, Angelo KM, Ritchey J, Greenberg DP, Muhammad RD, Brunette G et al. Addressing a yellow fever vaccine shortage — United States, 2016–2017. Morbidity and Mortality Weekly Report. 2017 May 5;66(17):457-459. https://doi.org/10.15585/mmwr.mm6617e2
Gershman, Mark D. ; Angelo, Kristina M. ; Ritchey, Julian ; Greenberg, David P. ; Muhammad, Riyadh D. ; Brunette, Gary ; Cetron, Martin S. ; Sotir, Mark J. / Addressing a yellow fever vaccine shortage — United States, 2016–2017. In: Morbidity and Mortality Weekly Report. 2017 ; Vol. 66, No. 17. pp. 457-459.
@article{59a282aae1a24477aefbae37e7552038,
title = "Addressing a yellow fever vaccine shortage — United States, 2016–2017",
abstract = "What is already known about this topic? Effective and safe yellow fever vaccines are available to prevent yellow fever disease among persons traveling to countries with yellow fever virus transmission and to comply with individual country yellow fever vaccination entry requirements; only one yellow fever vaccine (YF-VAX) is currently licensed for use in the United States. Periodic, temporary yellow fever vaccine shortages have occurred in the United States as a result of manufacturing problems, including a manufacturing complica­tion in 2016 that resulted in the loss of a large number of U.S.-licensed yellow fever vaccine doses. What is added by this report? To avoid a lapse in yellow fever vaccine availability to persons in the U.S. population for whom yellow fever vaccination is indicated, public health officials and private partners collaborated in pursuing an expanded access investigational new drug (eIND) application for the importation of Stamaril yellow fever vaccine into the United States. Stamaril is produced by Sanofi Pasteur, the manufacturer of the U.S.-licensed YF-VAX, and it uses the same vaccine substrain. A systematic, tiered process was developed to select clinics to participate in the eIND protocol, with the goal of reasonable accessibility to yellow fever vaccination for all U.S. residents, while assuring that clinic personnel could be ade­quately trained to participate in the protocol. What are the implications for public health practice? Providers need to be aware that there is a yellow fever vaccine shortage and there is a plan for providing safe vaccine at a limited number of clinics until the supply is replenished. Domestic production of yellow fever vaccine in the United States should resume in 2018, and as the eIND protocol is implemented, CDC and Sanofi Pasteur will need to continue to collaborate throughout site recruitment and training, partner to resolve issues that arise, and maintain communication with health care providers and the general public.",
author = "Gershman, {Mark D.} and Angelo, {Kristina M.} and Julian Ritchey and Greenberg, {David P.} and Muhammad, {Riyadh D.} and Gary Brunette and Cetron, {Martin S.} and Sotir, {Mark J.}",
year = "2017",
month = "5",
day = "5",
doi = "10.15585/mmwr.mm6617e2",
language = "English (US)",
volume = "66",
pages = "457--459",
journal = "Morbidity and Mortality Weekly Report",
issn = "0149-2195",
publisher = "Department of Health and Human Services",
number = "17",

}

TY - JOUR

T1 - Addressing a yellow fever vaccine shortage — United States, 2016–2017

AU - Gershman, Mark D.

AU - Angelo, Kristina M.

AU - Ritchey, Julian

AU - Greenberg, David P.

AU - Muhammad, Riyadh D.

AU - Brunette, Gary

AU - Cetron, Martin S.

AU - Sotir, Mark J.

PY - 2017/5/5

Y1 - 2017/5/5

N2 - What is already known about this topic? Effective and safe yellow fever vaccines are available to prevent yellow fever disease among persons traveling to countries with yellow fever virus transmission and to comply with individual country yellow fever vaccination entry requirements; only one yellow fever vaccine (YF-VAX) is currently licensed for use in the United States. Periodic, temporary yellow fever vaccine shortages have occurred in the United States as a result of manufacturing problems, including a manufacturing complica­tion in 2016 that resulted in the loss of a large number of U.S.-licensed yellow fever vaccine doses. What is added by this report? To avoid a lapse in yellow fever vaccine availability to persons in the U.S. population for whom yellow fever vaccination is indicated, public health officials and private partners collaborated in pursuing an expanded access investigational new drug (eIND) application for the importation of Stamaril yellow fever vaccine into the United States. Stamaril is produced by Sanofi Pasteur, the manufacturer of the U.S.-licensed YF-VAX, and it uses the same vaccine substrain. A systematic, tiered process was developed to select clinics to participate in the eIND protocol, with the goal of reasonable accessibility to yellow fever vaccination for all U.S. residents, while assuring that clinic personnel could be ade­quately trained to participate in the protocol. What are the implications for public health practice? Providers need to be aware that there is a yellow fever vaccine shortage and there is a plan for providing safe vaccine at a limited number of clinics until the supply is replenished. Domestic production of yellow fever vaccine in the United States should resume in 2018, and as the eIND protocol is implemented, CDC and Sanofi Pasteur will need to continue to collaborate throughout site recruitment and training, partner to resolve issues that arise, and maintain communication with health care providers and the general public.

AB - What is already known about this topic? Effective and safe yellow fever vaccines are available to prevent yellow fever disease among persons traveling to countries with yellow fever virus transmission and to comply with individual country yellow fever vaccination entry requirements; only one yellow fever vaccine (YF-VAX) is currently licensed for use in the United States. Periodic, temporary yellow fever vaccine shortages have occurred in the United States as a result of manufacturing problems, including a manufacturing complica­tion in 2016 that resulted in the loss of a large number of U.S.-licensed yellow fever vaccine doses. What is added by this report? To avoid a lapse in yellow fever vaccine availability to persons in the U.S. population for whom yellow fever vaccination is indicated, public health officials and private partners collaborated in pursuing an expanded access investigational new drug (eIND) application for the importation of Stamaril yellow fever vaccine into the United States. Stamaril is produced by Sanofi Pasteur, the manufacturer of the U.S.-licensed YF-VAX, and it uses the same vaccine substrain. A systematic, tiered process was developed to select clinics to participate in the eIND protocol, with the goal of reasonable accessibility to yellow fever vaccination for all U.S. residents, while assuring that clinic personnel could be ade­quately trained to participate in the protocol. What are the implications for public health practice? Providers need to be aware that there is a yellow fever vaccine shortage and there is a plan for providing safe vaccine at a limited number of clinics until the supply is replenished. Domestic production of yellow fever vaccine in the United States should resume in 2018, and as the eIND protocol is implemented, CDC and Sanofi Pasteur will need to continue to collaborate throughout site recruitment and training, partner to resolve issues that arise, and maintain communication with health care providers and the general public.

UR - http://www.scopus.com/inward/record.url?scp=85019011840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019011840&partnerID=8YFLogxK

U2 - 10.15585/mmwr.mm6617e2

DO - 10.15585/mmwr.mm6617e2

M3 - Article

C2 - 28472025

AN - SCOPUS:85019011840

VL - 66

SP - 457

EP - 459

JO - Morbidity and Mortality Weekly Report

JF - Morbidity and Mortality Weekly Report

SN - 0149-2195

IS - 17

ER -